Fig. 4
From: EGFR modulates complement activation in head and neck squamous cell carcinoma
Complement activation and expression of CRP in cetuximab resistant sublines. (a) HNSCC cell lines HN4 and HN5 were treated with increasing concentrations of cetuximab to yield resistant sublines HN4-cet and HN5-cet. (b) Using IFM deposition of C3 and TCC after incubation with NHS was assessed in HN4-cet and HN5-cet, and compared to their respective original cell lines set to 1. Bars represent the average of 10 representative fields. Error bars represent SEM. (c) Expression of CRP in resistant sublines HN4-cet and HN5-cet, was compared to the expression in the original cell lines HN4 and HN5 set to 1, using qPCR. Bars represent the average of 3 experiments. Error bars represent SEM. * p < 0.05, ** p < 0.01